“I Feel Like I Don’t Even Have HIV Anymore”—Facilitators, Barriers, and Experience regarding Use of Long-Acting Injectable Antiretroviral Therapy Among Persons with HIV in North Carolina
Authors:
- 1 July 2024
- journal article
- research article
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 38 (7) , 324-329
Abstract
As access to long-acting injectable antiretroviral therapy (LAI ART) expands, understanding patient perceptions and experiences around LAI should inform equitable scale-up and effective implementation strategies. This study used qualitative research design relying on semi-structured interviews conducted among persons with HIV (PWH) who were either virally suppressed on oral treatment (n = 11) or had received at least one dose of injectables (n = 7). Approximately half of participants identified as male (10/18) and most identified as African American (17/18). Among participants on oral ART, many described the prospect of injectable treatment as likely convenient and discreet, relieving the stress of remembering to take daily pill. Nearly all had heard of LAI ART prior to the interview, often from television or internet commercials. Most were excited about less frequent dosing, though expressed concern about the logistics involved in coming to clinic every two months. Many expressed uncertainties regarding the relative effectiveness of LAI ART compared with oral therapy and were wary of potential pain related to injections. In contrast, all persons on LAI ART described injection-site soreness as manageable. In addition to acknowledging the convenience of every-two-month injections, some persons receiving LAI ART expressed relief by lifting the emotional stress of taking a daily-pill that reminded them of their HIV positive status. Emerging clinical trial data supports the individual and public health benefits of LAI ART, regardless of prior viral-suppression; our work adds to a growing body of literature demonstrating the potential psychological benefits associated with this novel treatment modality for PWH regardless of recent viral-suppression.Keywords
This publication has 22 references indexed in Scilit:
- Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United StatesAIDS Patient Care and STDs, 2024
- Receipt of Injectable HIV Treatment in Clinic Versus at Home: Perspectives of Persons Living with HIV InfectionAIDS Patient Care and STDs, 2023
- Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs)Clinical Infectious Diseases, 2022
- Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income CountriesClinical Infectious Diseases, 2022
- Patient and Physician Preferences Regarding Long-Acting Pre-Exposure Prophylaxis and Antiretroviral Therapy: A Mixed-Methods Study in Southern California, USAAIDS Research and Human Retroviruses, 2022
- First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV ClinicClinical Infectious Diseases, 2022
- The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping ReviewAIDS Research and Human Retroviruses, 2021
- Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infectionAIDS Care, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionNew England Journal of Medicine, 2020